Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer. 28008156 2017
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease BEFREE Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings. 25999051 2015
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE Compared with RAS or PAX8/PPARG-positive TCs, BRAFV600E or RET/PTC-positive TCs were more often associated with stage III/IV disease (40% vs 15%, P < 0.001) and recurrence (10% vs 0.7%, P < 0.001; mean follow-up 33 ± 21 mo). 26258321 2015
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall. 24811481 2014
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE TSH receptor mRNA reverse transcription-polymerase chain reaction, the Veracyte and Asuragen commercial methods, and the noncommercial use of BRAF, RAS, RET/PTC, and PAX8/PPARγ testing have promising roles in the diagnosis and treatment of patients with nodular thyroid disease and thyroid cancer. 22984796 2013
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease BEFREE RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. 23436219 2013
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE FISH analysis using PPAR γ-specific probes for detection of PAX8-PPAR γ translocation in follicular thyroid neoplasms. 23100233 2013
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE The aim of the present study was to develop a method for the detection of chimeric PAX8-PPARG transcripts in formalin-fixed paraffin-embedded (FFPE) thyroid tumor samples by conventional RT-PCR. 22179975 2012
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease BEFREE Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements. 21878896 2011
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease BEFREE In this study, a group of 60 follicular thyroid neoplasms [18 FTC, 1 Hurthle cell carcinoma (HCC), 24 follicular thyroid adenomas (FTA), 5 Hurthle cell adenomas (HCA), and 12 follicular variants of papillary thyroid carcinomas (FV-PTC)] were analyzed to determine the prevalence of the PAX8-PPARG translocation by fluorescence in situ hybridization. 19963130 2010
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease BEFREE The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs). 19147628 2009
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE Underexpression of PPARgamma is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin. 19724872 2009
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease LHGDN Here, we report our discovery of a novel CREB3L2-PPARgamma fusion mutation in thyroid carcinoma with t(3;7)(p25;q34), showing that a family of somatic PPARgamma fusion mutations exist in thyroid cancer. 18757431 2008
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease BEFREE As such, this article addresses the following aspects of intragenic mutations in thyroid cancer: thyroid stimulating hormone receptor and guanine-nucleotide-binding proteins of the stimulatory family mutations in hyperfunctioning tumors; mutations in RAS and other genes and aneuploidy; PAX8-PPARgamma rearrangements; BRAF mutations; mutations in oxidative phosphorylation and Krebs cycle genes in Hürthle cell tumors; mutations in succinate dehydrogenase genes in medullary carcinoma and C-cell hyperplasia; and mutations in TP53 and other genes in poorly differentiated and anaplastic carcinomas. 18502330 2008
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease BEFREE The common somatic genetic changes in thyroid cancer of follicular cell origin (RET/PTC, NTRK, RAS, BRAF, PAX8-PPARgamma) are generally mutually exclusive, with distinct genotype-histologic subtype of thyroid cancer and genotype-phenotype associations observed. 18043251 2008
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease LHGDN Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. 18509005 2008
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease BEFREE Here, we report our discovery of a novel CREB3L2-PPARgamma fusion mutation in thyroid carcinoma with t(3;7)(p25;q34), showing that a family of somatic PPARgamma fusion mutations exist in thyroid cancer. 18757431 2008
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 GeneticVariation disease LHGDN PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. 16219715 2006
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist that has been shown to induce differentiation, cell cycle arrest, and apoptosis in a variety of human cancers including thyroid cancer. 17188145 2006
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease LHGDN The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. 16352687 2006
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE Using this mutant mouse, we tested the hypothesis that the peroxisome proliferator-activated receptor gamma (PPARgamma) could function as a tumor suppressor in thyroid cancer in vivo. 16314832 2006
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Therapeutic disease CTD_human Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon. 15785241 2005
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 AlteredExpression disease BEFREE Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon. 15785241 2005
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease LHGDN Our investigations document that human thyroid cancer cell lines commonly express PPARgamma, but chromosomal translocations involving PPARgamma are uncommon. 15785241 2005
CUI: C0040136
Disease: Thyroid Neoplasm
Thyroid Neoplasm
0.400 Biomarker disease BEFREE The purpose of this study was to evaluate the possibility for the therapeutic effect of PPARgamma ligands against anaplastic thyroid tumor in vitro. 14654945 2004